Society for Immunotherapy of Cancer (SITC) leaders have prioritized the following areas of focus in addressing regulatory issues relating to the field of cancer immunotherapy:
SITC has forged strategic relationships with government and regulatory entities from around the world to address key regulatory issues including formal liaison relationships with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute/National Institutes of Health (NCI/NIH).
If you have partnership or policy-related questions, please contact SITC staff at SITCExecOffice@sitcancer.org.
Click here to view a complete listing of these institutions.
There is an urgent need among practicing oncologists and nurses for treatment algorithms that guide management of immunotherapy-related toxicities. Similarly, standardized templates for reporting adverse events in clinical trials are needed in order to facilitate monitoring and reporting of toxicities, an effort which is considered a high priority by the U.S. Food and Drug Administration.
To this end, SITC took the lead to convene a one-day Toxicity Management Workshop on Friday, March 31, 2017, in Washington, D.C. Click here to learn more about this event.
Join SITC members, Drs. Vincenzo Bronte, Lorenzo Galluzzi and Jérôme Galon, for the Primer on Cancer Immunology and Immunotherapy at the International Conference on Immunotherapy Radiotherapy Combinations Sept. 20–22 in Paris. Attention SITC members! ...
This two day program is divided into a lectures series presented by world class scientists in the field of immuno-oncology, and a hands-on workshop laboratory to explore the optimization and troubleshooting of Opal staining, multispectral image acquisition ...
Currently scfvs, antibody-derived single chain variable fragment based CAR to target CD19 antigen is the most common CAR strategy clinically used. But based on the cited article, tumor cells can be targeted also through use of non-antibody based approahes.This ...
Dear Dr. Ramakrishna, Below please find a short summary of immunotherapies targeting CD123, CD33. All can be found on clinicaltrials.gov. I have heard that the City of Hope (COH) CAR T cells anti-CD123 study is showing early promise, but I have no ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com